United Therapeutics (UTHR) EVP & General Counsel sells 8,300 shares after option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. As EVP & General Counsel, he exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, then sold 8,300 shares in multiple open-market trades at weighted average prices around $574–$578 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the trades, he directly owned 45,172 shares of United Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 8,300 shares ($4,787,597)
Net Sell
7 txns
Insider
MAHON PAUL A
Role
EVP & GENERAL COUNSEL
Sold
8,300 shs ($4.79M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 8,300 | $0.00 | -- |
| Exercise | Common Stock | 8,300 | $146.03 | $1.21M |
| Sale | Common Stock | 200 | $574.034 | $115K |
| Sale | Common Stock | 1,640 | $575.3692 | $944K |
| Sale | Common Stock | 1,800 | $576.3848 | $1.04M |
| Sale | Common Stock | 3,366 | $577.388 | $1.94M |
| Sale | Common Stock | 1,294 | $578.2099 | $748K |
Holdings After Transaction:
Stock Option — 8,600 shares (Direct);
Common Stock — 53,472 shares (Direct)
Footnotes (1)
- This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. This transaction was executed in multiple trades at prices ranging from $573.865 to $574.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $574.95 to $575.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $575.97 to $576.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $577.00 to $577.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $578.00 to $578.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 8,300 shares
Exercise price: $146.03 per share
Shares sold: 8,300 shares
+2 more
5 metrics
Options exercised
8,300 shares
Stock options converted into common stock on April 16, 2026 at $146.03 exercise price
Exercise price
$146.03 per share
Strike price for 8,300 stock options exercised into United Therapeutics common stock
Shares sold
8,300 shares
Total United Therapeutics common shares sold in multiple open-market trades on April 16, 2026
Sale prices
$574.03–$578.21 per share
Approximate range of weighted average sale prices across reported open-market transactions
Post-transaction holdings
45,172 shares
United Therapeutics common shares directly owned by Paul A. Mahon after the transactions
Key Terms
Rule 10b5-1 plan, Stock Option, open-market sale, weighted average price, +1 more
5 terms
Rule 10b5-1 plan regulatory
"exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option financial
"security_title": "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did UTHR executive Paul A. Mahon report in this Form 4 filing?
Paul A. Mahon reported an option exercise and related share sales. He exercised stock options for 8,300 United Therapeutics shares at $146.03 each and then sold 8,300 shares in multiple open-market trades, all under a pre-arranged Rule 10b5-1 trading plan.
What stock options did Paul A. Mahon exercise in United Therapeutics (UTHR)?
He exercised options covering 8,300 United Therapeutics shares. These options had an exercise price of $146.03 per share and were originally granted as stock options exercisable into common stock, with the full 8,300 underlying shares converted in this transaction.
Were Paul A. Mahon’s United Therapeutics (UTHR) sales open-market transactions?
Yes, the filing describes the sales as open-market transactions. Each sale is coded with “S” for sale and labeled as a sale in the open market or private transaction, with weighted average prices reported and detailed intraday price ranges available upon request.